Research Paper Volume 13, Issue 21 pp 24136—24154

Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort

class="figure-viewer-img"

Figure 3.

DDR mutations association with prognosis in 7 distinct cancers. (AG) Association of DDR mutations with prognosis in 7 cancers in the MSKCC cohort; (HN) Association of DDR mutations with prognosis in 7 cancers in the TCGA cohort. Cancer types that exhibited the survival benefits of NLRP3 mutations in the MSKCC and TCGA cohorts were respectively colored with green and blue.